The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 27397499 |
21 |
Discovery of novel dihydrobenzofuran cyclopropane carboxylic acid based calcium sensing receptor antagonists for the treatment of osteoporosis. |
Merck Research Laboratories |
| 24215889 |
21 |
Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism. |
Amgen |
| 23499504 |
31 |
New potent calcimimetics: II. Discovery of benzothiazole trisubstituted ureas. |
Galapagos |
| 23465611 |
61 |
New potent calcimimetics: I. Discovery of a series of novel trisubstituted ureas. |
Galapagos |
| 20727747 |
15 |
Discovery of a class of calcium sensing receptor positive allosteric modulators; 1-(benzothiazol-2-yl)-1-phenylethanols. |
Acadia Pharmaceuticals |
| 19821575 |
47 |
Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues. |
Glaxosmithkline |
| 15149704 |
3 |
N2-benzyl-N1-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor. |
Upr 2301 Centre National De La Recherche Scientifique |
| 19442519 |
14 |
The discovery of novel calcium sensing receptor negative allosteric modulators. |
Pfizer |
| 21353570 |
25 |
Novel and potent calcium-sensing receptor antagonists: discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent. |
Takeda Pharmaceutical |
| 21306167 |
26 |
Discovery of novel and potent orally active calcium-sensing receptor antagonists that stimulate pulselike parathyroid hormone secretion: synthesis and structure-activity relationships of tetrahydropyrazolopyrimidine derivatives. |
Takeda Pharmaceutical |
| 24900301 |
24 |
Discovery of a Potent and Short−Acting Oral Calcilytic with a Pulsatile Secretion of Parathyroid Hormone |
TBA |
| 21055954 |
21 |
Synthesis and structure-activity relationship of tetrahydropyrazolopyrimidine derivatives--a novel structural class of potent calcium-sensing receptor antagonists. |
Takeda Pharmaceutical |
| 20708930 |
36 |
The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core. |
Amgen |
| 20685119 |
37 |
Penta-substituted benzimidazoles as potent antagonists of the calcium-sensing receptor (CaSR-antagonists). |
Novartis Institutes For Biomedical Research |
| 20472433 |
37 |
New aminopropandiol derivatives as orally available and short-acting calcium-sensing receptor antagonists. |
Central Pharmaceutical Research Institute |
| 20218623 |
68 |
Emerging targets in osteoporosis disease modification. |
Amgen |
| 20158186 |
48 |
1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists. |
Novartis Institutes For Biomedical Research |
| 19835382 |
18 |
Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. |
Amgen |
| 19492813 |
56 |
Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. |
Glaxosmithkline |
| 16216508 |
44 |
Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 15863312 |
17 |
Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. |
Nps Pharmaceuticals |
| 15745796 |
22 |
3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. |
Nps Pharmaceuticals |
| 29724589 |
40 |
Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. |
Mitsubishi Tanabe Pharma |
| 28916340 |
23 |
Identification of potent, nonabsorbable agonists of the calcium-sensing receptor for GI-specific administration. |
Glaxosmithkline |
Search and Browse
